Promus - Registry Experience at the Washington Hospital Center, Drug-eluting Stent (DES) (P-REWARDS)
Status
Conditions
Details and patient eligibility
About
Single-center registry of patients treated with at least one Promus, everolimus-eluting, Stent, with the primary objective to assess clinical success and safety at 30 days, 6 months and 1 year post-implantation.
Full description
Interventional cardiology was revolutionized by the invention of stents, initially with the bare-metal stents (BMS) and recently with the drug-eluting stents (DES). The everolimus eluting stents have shown very promising results in randomized clinical trials, demonstrating a reduction of clinical and angiographic restenosis in comparison to BMS, and comparable clinically-driven target lesion revascularization rates in comparison with sirolimus-eluting stents. While registry data is available from outside of the United States, it will be important to collect "real-world" data regarding the stent usage and outcomes in the United States. In this study we propose to follow patients who received at least one Promus® Stent for at least 1 year post initial stent implantation.
Sex
Ages
Volunteers
Inclusion criteria
- Patients, male or female, >18 years of age
- Patients who received at least one Promus drug-eluting stent at the Washington Hospital Center
Exclusion criteria
- N/A
Trial design
0 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal